

## Comparison of Fasting Glucose, and HbA<sub>1c</sub> for Use in Screening for Type 2 Diabetes

Patricia A. Metcalf<sup>1,2\*</sup>, Cam Kyle<sup>3</sup>, Tim Kenealy<sup>4</sup>, Gerhard Sundborn<sup>1</sup> and Rod T. Jackson<sup>1</sup>

<sup>1</sup>Division of Epidemiology and Biostatistics, School of Population Health, Tamaki Campus, University of Auckland, 261 Morrin Road, St Johns, Auckland 1072, New Zealand

<sup>2</sup>Department of Statistics, University of Auckland, Private Bag 92019, Auckland Mail Center, Auckland 1010, New Zealand

<sup>3</sup>LabPlus, Auckland City Hospital, and Department of Molecular Medicine, University of Auckland, Auckland, New Zealand

<sup>4</sup>Departments of Medicine, and General Practice and Primary Health Care, University of Auckland, Private Bag 92019, Auckland Mail Center, Auckland 1010, New Zealand

**\*Corresponding Author:** Dr. Patricia Metcalf, Division of Epidemiology and Biostatistics, School of Population Health, Tamaki Campus, University of Auckland, 261 Morrin Road, St Johns, Auckland 1072, New Zealand; Tel: (64-9)-9237715; Fax: (64-9)-3737018; E-mail: [p.metcalf@auckland.ac.nz](mailto:p.metcalf@auckland.ac.nz)

**Citation:** Patricia A. Metcalf, Cam Kyle, Tim Kenealy, Gerhard Sundborn and Rod T. Jackson (2016) Comparison of Fasting Glucose, and HbA<sub>1c</sub> for Use in Screening for Type 2 Diabetes. *Diabetes Res Metab* 1: 004.

**Copyright:** © 2016 Patricia A. Metcalf, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted Access, usage, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

**Background:** Various cut-offs for fasting (FBP) and 2-hour plasma glucose (2-hr PG) post oral glucose test (oGTT) have been proposed. More recently, it has been recommended that glycated haemoglobin (HbA<sub>1c</sub>) replace FBG and the oGTT.

**Objective:** To compare the usefulness of fasting glucose alone, and HbA<sub>1c</sub> with the World Health Organisation (WHO) recommended fasting and 2-hr post oral glucose tolerance test glucose for use as screening tests for Type 2 diabetes mellitus.

**Research Design and Methods:** Data were from 3,465 participants aged 35-74 years who were from the Diabetes, Heart and Health Survey that was carried out between 2002 and 2003. Participants underwent a 75g oGTT and HbA<sub>1c</sub> was determined by ion-exchange high-performance liquid chromatography.

**Results:** Using the American Diabetes Association (ADA) fasting glucose cut-off of 7.0 mmol/L (126 mg/dL) alone would miss 46.9% of participants with diabetes diagnosed by oGTT criteria, comprising 57.1% of Europeans, 54.5% of Māori, 32.8% of Pacific and 57.1% of Asian people. Using an HbA<sub>1c</sub> only with cutoff of 48 mmol/mol (6.5%) would miss 59.2% of participants with WHO diagnosed diabetes, comprising 76.2% Europeans, 88.4% Māori, 50.0% Pacific, and 88.4% of Asian people. Compared to the oGTT and ADA fasting glucose criteria, an HbA<sub>1c</sub> of  $\geq 48$  mmol/mol had a sensitivity of 55.1% and a specificity of 96.7% (WHO), and 31.3% sensitivity and 99.5% specificity (ADA), respectively.

**Conclusions:** Compared to the WHO oGTT criteria for diagnosing diabetes, fasting glucose alone and HbA<sub>1c</sub> are less sensitive, but more specific.

**Keywords:** oGTT; HbA<sub>1c</sub>; Diabetes; Diagnostic tests.

**Abbreviations:** HbA<sub>1c</sub>: Glycated haemoglobin or haemoglobin A<sub>1c</sub>; WHO: World Health Organisation; oGTT: Oral glucose tolerance test; ADA: American Diabetes Association; FPG: Fasting plasma glucose; 2-hr PG: 2 hour post 75g oral glucose load; IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance.

## Introduction

The World Health Organization (WHO) has made a number of recommendations for the diagnosis of diabetes mellitus between 1965 and 2006 [1-5]. The diagnosis of diabetes has been based on the fasting plasma glucose (FPG) and the oral glucose tolerance test (oGTT) with a FPG of  $\geq 8.0$  mmol/L in 1980,  $\geq 7.8$  mmol/L in 1985 and  $\geq 7.0$  mmol/L in 1999 and 2006, and a 2 hour post 75g oral glucose load (2-hr PG) of  $\geq 11.1$  mmol/l since 1985. The American Diabetes Association (ADA) introduced new diagnostic guidelines in 1997 [6]. A lower FPG level ( $\geq 7.0$  mmol/l for venous plasma) was recommended for the diagnosis of diabetes in both clinical and epidemiological settings.

More recently in 2009, the ADA recommended that glycated haemoglobin (HbA<sub>1c</sub>) be used in place of an oGTT with a threshold HbA<sub>1c</sub> of  $\geq 6.5\%$  ( $\geq 48$  mmol/mol) to diagnose diabetes [7]. However, because of the low sensitivity of the HbA<sub>1c</sub> test in some populations [8-11], and ethnic disparities in the relationship between HbA<sub>1c</sub> and glucose levels [12-14], the ADA now recommends that diagnosis can be based on either HbA<sub>1c</sub> criteria or FPG criteria. Although seldom performed, the 2-h PG value after a 75g oGTT [15] could be used, with cut-offs' similar to the WHO cut-off levels [4].

The purpose of this study was to investigate the diagnostic utility of FPG and glycated hemoglobin (HbA<sub>1c</sub>) in classifying the WHO oGTT diagnosed diabetes in a multiethnic sample of adults.

## Research Design and Methods

The Auckland Diabetes, Heart and Health Survey was carried out between December 2001 and November 2003 in 4,049 participants. People with previously diagnosed diabetes mellitus (n=466), missing oral glucose

tolerance test (oGTT) (n=19), missing HbA<sub>1c</sub> (n=5) or missing 2-h PG (n=94) results were excluded, leaving 3,465. These participants comprised 48.0% males, 46.8% Europeans, 24.7% Māori, 21.5% Pacific and 6.9% Asian people. Ethical Committee approval was obtained from the Auckland Ethics Committees (Reference 2001/133).

Interviews were carried out in community venues or clinics close to participant's homes. Personnel were trained in the administration of the questionnaires and in taking blood pressure and other measurements. Ethnicity was defined according to the 2006 NZ census [16].

## Biochemical Assessment

Participants fasted from 10pm the evening before the interview. A 75-g oGTT was carried out in participants who had not been previously diagnosed with diabetes, and morning FPG and 2-h PG post Glucaid drink samples were collected for glucose measurement. Plasma glucose was measured using an enzymatic method (Glucose oxidase; Roche Hitachi method).

Categorisation of glucose tolerance status was evaluated by 1998 WHO criteria (FPG  $\geq 7.0$  mmol/l and/or 2-h PG of  $\geq 11.1$  mmol/l for diabetes, 2-h PG  $< 7.0$  mmol/l and 2-h PG 7.8-11.0 mmol/l for impaired glucose tolerance (IGT) [17], and by ADA criteria (using the FPG of  $\geq 7.0$  mmol/l for diabetes and 6.1 to 6.9 mmol/l for impaired fasting glycaemia (IFG)) [6]. The ADA criteria for diabetes is an HbA<sub>1c</sub>  $\geq 48$  mmol/mol (6.5%) [7].

HbA<sub>1c</sub> was measured by ion-exchange high-performance liquid chromatography on a Biorad Variant II instrument. The in-house inter-batch coefficients of variation for low control material were glucose 2.1%, and HbA<sub>1c</sub> 1.7%, those of abnormal (high) control were glucose 1.3% and HbA<sub>1c</sub> 2.1%. The laboratory maintained ongoing acceptable performance in the Royal Australasian College of Pathologists external proficiency QAP programme for all tests and continuous accreditation against ISO15189.

## Statistical Analyses

The sensitivity, specificity, positive and negative predictive values were calculated. The sensitivity is the proportion of people with undiagnosed Type 2 diabetes who are correctly identified by the test (percentage true positives). The specificity is the proportion of people without undiagnosed Type 2 diabetes who are correctly identified as such by the test. The positive predictive value is the proportion of people with a positive result who have undiagnosed Type 2 diabetes. The negative predictive value is the proportion of people with a negative result who do not have undiagnosed Type 2 diabetes.


The weighted kappa ( $\kappa$ ) statistic was used to assess the agreement between the two classification systems beyond agreement expected by chance for participants previously unknown to have diabetes [18]. A value close to 1 indicates perfect agreement and a value  $< 0.6$  represents poor to moderate agreement [18].

The predictive characteristics of the tests were assessed by calculating Receiver Operator Curves (ROCs) (sensitivity versus  $1 - \text{specificity}$ ). The area under the ROC curve (AUC) shows the ability to discriminate people with and without diabetes. The AUC distinguish between non-predictive ( $\text{AUC} = 0.5$ ), less predictive ( $0.5 < \text{AUC} < 0.7$ ), moderately predictive ( $0.7 < \text{AUC} < 0.9$ ), highly predictive ( $0.9 < \text{AUC} < 1$ ) and perfect prediction ( $\text{AUC} = 1$ ). An AUC of 1 is a perfect test, whereas an AUC of 0.5 is an uninformative test [19]. The two diagnostic tests were compared using the methods of Greenhouse and Mantel [20].

## Results

The mean (SD) age of males was 53.3 (11.59) years and for females was 52.6 (11.56) years. All participants were categorised according to the 1997 ADA criteria and the 1998 WHO criteria (Table 1). Prevalence of diabetes by WHO criteria was 1.88 times higher than by FPG ADA criteria. However, the prevalence of IGT was over four times higher than IFG. The ADA criteria (using FBG only) would miss 46.9% of participants with WHO diagnosed diabetes (using both FPG and 2-h PG after the oGTT). Overall, the percentage agreement between the two diagnostic criteria (the sum of the diagonal numbers expressed as a percentage) was 86.5%, with 468 (13.5%) not concordant by the two criteria. In those participants who were classified as having diabetes by the WHO criteria, 17.7% would have been classified normal and 29.3% as IFG using ADA criteria. Only 32% had both 2-hr PG  $\geq 11.1$  mmol/L and FPG  $\geq 7.0$  mmol/L (Figure 1). The overall weighted  $\kappa$  was 0.48 (95% CI: 0.43-0.52), indicating moderate agreement between the two tests. Prevalence of diabetes by WHO criteria was 1.8 times higher than by HbA<sub>1c</sub> criteria (Table 1). The percentage agreement between the two diagnostic criteria was 59.0%, giving 41% discordance by the two criteria. In those participants who were classified as having diabetes by the WHO criteria, 8.8% would have been classified normal and 36.1% as high-normal using HbA<sub>1c</sub> criteria. Only 55% had an HbA<sub>1c</sub>  $\geq 48$  mmol/mol (Figure 1). The weighted kappa was only 0.24 (95% CI: 0.22-0.27) indicating poor agreement between the two tests.

**Figure 1:** Prevalence of diabetes by oGTT status of elevated FPG only, elevated 2-hr PG only, both fasting and 2-hr PG, and elevated HbA<sub>1c</sub>, in all participants with WHO classified diabetes and by ethnic group.



**Table 1:** Comparison of diagnostic criteria for glucose intolerance by the 1997 ADA and 1998 WHO criteria. Values are number (%).

	ADA FPG criteria				HbA <sub>1c</sub> (mmol/mol)			
	Normal	IFG	Diabetes	Total	<39	39-<48	≥ 48	Total
<b>WHO criteria<sup>1</sup></b>	Weighted kappa 0.48 (0.43-0.52)				Weighted kappa 0.24 (0.22-0.27)			
Normal	2,843 (82.1)	121 (3.5)	0	2,964 (85.5)	1,746 (50.3)	1,164 (33.6)	54 (1.6)	2964 (85.5)
IGT	278 (8.0)	76 (2.2)	0	354 (10.2)	85 (2.5)	212 (6.1)	57 (1.6)	354 (10.2)
Diabetes	26 (0.7)	43 (1.2)	78 (2.3)	147 (4.2)	13 (0.4)	53 (1.5)	81 (2.3)	147 (4.2)
Total	3,147 (90.8)	240 (6.9)	78 (2.3)	3,465 (100.0)	1,844 (53.2)	1,429 (41.2)	192 (5.5)	3,465 (100.0)
<b>HbA<sub>1c</sub> (mmol/mol)</b>	Weighted kappa 0.19 (0.17-0.22)							
< 39	1,801 (52.0)	1,275 (36.8)	71 (2.0)	3,147 (90.8)				
39-<48	43 (1.2)	136 (3.9)	61 (1.8)	240 (6.9)				
≥ 48	0 (0.0)	18 (0.5)	60 (1.7)	78 (2.2)				
Total	1,844 (53.2)	1,429 (41.2)	192 (5.6)	3,465 (100.0)				

1. Based on both FPG and 2-hr PG values IGT = impaired glucose tolerance; IFG = impaired fasting glucose.

The ADA prevalence of diabetes was only 1.3 times higher than the HbA<sub>1c</sub> criteria (Table 1). The percentage agreement of 58% was similar to the WHO versus HbA<sub>1c</sub>. Only 32% of participants classified as having diabetes by the ADA criteria had a high-normal HbA<sub>1c</sub>. However, the weighted kappa was only 0.19 (95% CI: 0.17-0.22) indicating poor agreement between the two tests.


Figure 1 shows the proportions with elevated FPG only, 2-hr PG only or both, and the proportion with an elevated HbA<sub>1c</sub> overall and by ethnicity. No Asians who were diagnosed with WHO classified diabetes had a FPG ≥ 7.0mmol/L, i.e. all were on the basis of an elevated 2-hr PG oGTT result. In others diagnosed as diabetic using the WHO oGTT criteria, an elevated 2-hr PG was present in more than 50% of Europeans, Māori and Asians, but in only 33% of Pacific people. Less than 50% in each ethnic group had both elevated FPG and 2-hr PG levels. Only 17% of European, 39% Māori, 36% of Pacific and 43% of Asian participants with diabetes had both 2-hr PG ≥ 11.1 mmol/L and FPG ≥ 7.0 mmol/L. While more than 50% of Māori, Pacific and Asians diagnosed as diabetic using WHO oGTT criteria had an elevated HbA<sub>1c</sub> (≥48 mmol/mol), a low proportion of

Europeans (24%) satisfied this criteria (Figure 1). Ethnic differences in diagnostic rates for prediabetes (using IGT, IFG and HbA<sub>1c</sub>) are shown in Appendix 1.

The Pearson correlation coefficients between FPG and 2-hr-PG was 0.64, between FPG and HbA<sub>1c</sub> was 0.71 and between 2-hr glucose and HbA<sub>1c</sub> was 0.60. Quadratic regression analysis indicated a significant relationship between fasting and 2 hour measures of glucose homeostasis (model R<sup>2</sup> = 0.52). According to this model, the FPG that best predicted a 2 hour post-glucose level of 11.1 mmol/L was 6.3 mmol/L (95% CI: 5.1-7.5 mmol/L).

The relationship between mean plasma glucose and HbA<sub>1c</sub> by ethnic group is shown in Figure 2. This graph shows that for a given mean plasma glucose level, Pacific, Māori and Asians have a higher HbA<sub>1c</sub> compared to Europeans, particularly at higher mean plasma glucose levels. The quadratic regression coefficients are also reported, together with the model percentage of variation explained (R<sup>2</sup>). The percentage of variation explained by the model was highest for Pacific and Asian people with R<sup>2</sup> > 0.8, followed by Māori (R<sup>2</sup> = 0.67), and was lowest in Europeans (R<sup>2</sup> = 0.43).

**Figure 2:** Ethnic comparison of relationship between mean of fasting and 2-hr glucose concentrations.



The areas under the ROC curves (AUC's) for diabetes mellitus overall, and by ethnic group are shown in Table 2. These were moderately predictive for HbA<sub>1c</sub>, and highly predictive for FPG and 2-hr PG and the results were similar in all ethnic groups. On comparing the tests for the column labelled “All”, FPG was significantly better than HbA<sub>1c</sub> (P = 0.002). However, there was no significant difference between the FPG and 2-hr PG AUC's (P=0.1369). The AUC's for IGT and IFG are shown in Appendix 2.

**Table 2:** Areas under the curve (AUC and 95% CI) for diabetes mellitus and 95% confidence interval (95% CI) for Receiver Operator curves for each test overall and by ethnicity.

	All	Europeans	Māori	Pacific	Asians
HbA <sub>1c</sub>	0.87 (0.84,0.97)	0.85 (0.79,0.91)	0.85 (0.75,0.94)	0.91 (0.86,0.95)	0.92 (0.84,1.00)
FPG	0.94 (0.91,0.96)	0.92 (0.86,0.97)	0.95 (0.92,0.99)	0.95 (0.91,0.99)	0.87 (0.75,0.99)
2-hr PG	0.96 (0.94,0.98)	0.97 (0.94,1.00)	1.00 (1.00,1.00)	0.93 (0.88,0.98)	1.00 (1.00,1.00)

Sensitivities, specificities, predictive values positive and predictive values negative overall and by ethnicity for HbA<sub>1c</sub> compared to the WHO and ADA criteria are shown in Table 3. The sensitivity and negative predictive values were higher for the WHO criteria and specificity and positive predictive value were higher for the ADA criteria.

Sensitivities were highest for Māori, Pacific and Asians, and higher for the ADA criteria compared to the WHO criteria. Both methods were highly specific. Predictive value positive were relatively low by both methods and in all ethnicities, whereas the positive predictive values negative was high in both methods and all ethnicities.

**Table 3:** Sensitivity, specificity, predictive value positive, predictive value negative and weighted kappa ( $\kappa$ ) for HbA<sub>1c</sub> compared to WHO and ADA criteria.

	<b>WHO criteria</b>	<b>ADA criteria</b>
<b>All</b>		
Weighted $\kappa$	0.24 (0.22-0.27)	0.19 (0.17-0.22)
Sensitivity	55.1%	31.3%
Specificity	96.7%	99.5%
PVP	42.2%	76.9%
PVN	98.0%	96.1%
<b>Europeans</b>		
Weighted $\kappa$	0.27 (0.22-0.33)	0.21 (0.16-0.26)
Sensitivity	23.8%	38.9%
Specificity	99.4%	99.3%
PVP	55.6%	38.9%
PVN	98.0%	99.3%
<b>Māori</b>		
Weighted $\kappa$	0.25 (0.19-0.31)	0.19 (0.14-0.25)
Sensitivity	51.5%	93.3%
Specificity	97.9%	98.6%
PVP	50.0%	53.8%
PVN	98.1%	99.9%
<b>Pacific</b>		
Weighted $\kappa$	0.27 (0.22-0.32)	0.25 (0.20-0.30)
Sensitivity	67.2%	82.1%
Specificity	93.9%	93.1%
PVP	48.1%	39.5%
PVN	97.1%	98.9%
<b>Asians</b>		
Weighted $\kappa$	0.37 (0.25-0.49)	0.31 (0.18-0.43)
Sensitivity	50.0%	83.3%
Specificity	98.2%	97.4%
PVP	63.6%	45.5%
PVN	96.9%	99.6%

PVP = predictive value positive; PVN = predictive value negative.

Table 4 shows the sensitivity, specificity, positive and negative predictive values for the standard diagnostic criteria, with the value giving equal weight to false positives and false negatives, and the value that maximised the

sensitivity and specificity for FPG, and HbA<sub>1c</sub>. When looking at the single tests and different cut-off levels, the highest sensitivity was found for HbA<sub>1c</sub> levels  $\geq 40$  mmol/mol (5.8%).

**Table 4:** Selected threshold values of fasting plasma glucose (FPG), and HbA<sub>1c</sub> with associated test sensitivity, specificity, positive (PV+) and negative (PV-) predictive value compared to the oGTT.

Threshold	FPG (mmol/L)			HbA <sub>1c</sub> (%)		
	$\geq 5.8^1$	$\geq 6.4^2$	$\geq 7.0^3$	$\geq 40^1$	$\geq 42^2$	$\geq 48^3$
Sensitivity (%)	85.7	71.4	53.0	85.0	73.5	55.1
Specificity (%)	87.7	97.5	100.0	73.0	85.8	96.7
PV+ (%)	23.6	55.9	100.0	12.3	18.7	42.2
PV- (%)	99.3	98.7	98.0	99.1	98.6	98.0

1 = Maximizing the sensitivity and specificity.

2 = Giving equal weight to false negatives and false positives.

3 = Standard diagnostic criteria.

## Discussion and Conclusions

In the present study HbA<sub>1c</sub> identified 55.1% of diabetes diagnosed by oGTT (WHO criteria), and 2-hr PG alone identified a similar 46.9% (Figure 1). However, FPG alone only identified 21.1% with WHO diagnosed diabetes. In contrast, a study in Saudi Arabia reported that HbA<sub>1c</sub>, FPG alone, and 2-hr PG alone identified 69.6%, 43.2% and 64.2, respectively [21]. A study in China reported lower numbers of diagnosed diabetes using HbA<sub>1c</sub> (34.4%), FPG alone (23.5%), 2-hr PG alone (11.5%) and both (11.5%) [22]. Similarly, a study in Spain reported that HbA<sub>1c</sub> alone, FPG alone, and 2-hr PG alone identified 15.4%, 32.3% and 98.5%, respectively [23]. The latter study reported that all participants with elevated FPG also had an elevated 2-hr PG. This was not the case in the current or other former studies.

The AUC for HbA<sub>1c</sub> compared to the oGTT diagnosed diabetes in the current study was 0.87 (Table 2). This compares well with previous studies that have reported AUC's for HbA<sub>1c</sub> between 0.64 in Iranian adults [24] to 0.96 in Bulgarian adults [25]. For FPG, the AUC was 0.95 in the current study. This was higher than previous studies that reported between 0.71 in Spanish adults [26] to 0.79 in Egyptian adults [27]. The AUC for 2-hr PG in the current study was 0.96 which was higher than the 0.71 [26] and 0.79 [28] reported in two studies from Spain.

The imperfect concordance of HbA<sub>1c</sub> and glucose criteria reflects that fact that there are inter-individual, and inter-ethnic differences, in HbA<sub>1c</sub> formation with variation in rate of glucose entry into red cells [29], variation in red cell turnover (even in subjects with normal haematology parameters [30], and other variations in red cell parameters and physiology such as intracellular iron levels [31] and oxidation status [32]. Indeed, genetic (GWAS) analysis indicates that glucose variation contributes only about 1/3 of total variation in HbA<sub>1c</sub> [33].

## Correlations

A higher correlation between FPG and HbA<sub>1c</sub> ( $r=0.71$ ) than between 2-hr PG and HbA<sub>1c</sub> ( $r=0.60$ ) has been observed previously. In general, correlations between FBG and HbA<sub>1c</sub> have ranged from 0.47 to 0.82 [25, 38, 40, 43, 45, 56, 57] and between 2-hr PG and HbA<sub>1c</sub> from 0.49 to 0.78 [25, 38, 40, 45, 57] with an outlier in an Italian population of 0.20 for this latter correlation [56]. Ko et al. also reported the correlations between FBG and 2hr glucose ( $r=0.74$ ) [57]. These results and those reported here suggest that HbA<sub>1c</sub> better reflects long-term mean FPG as well as post-load glucose.

We have previously reported a quadratic relationship between FPG and 2-hr PG levels in participants from a multi-ethnic workforce that explained 57.7% of the variation [58]. However, that model predicted a FPG of 7.3 mmol/L (95% CI: 6.0-8.5) for 2-hr PG of 11.1 mmol/L. That compares with 6.3 mmol/L (95% CI: 5.1-7.5) found in the current study explaining 52.6% of the variation (difference not significant).

### WHO oGTT vs ADA FBG

Results from the current study (Figure 1) confirm the findings of previous studies showing that FPG alone diagnoses only about half as many patients with diabetes as does oGTT. A single FPG  $\geq 7.0$  mmol/L (126 mg/dL) identified only 21.1% of participants with Type 2 diabetes by oGTT (WHO) criteria. Other studies have reported that 50-70% of people with diabetes diagnosed by oGTT have FPG levels  $< 7.0$  mmol/L [34, 35].

### HbA<sub>1c</sub> versus WHO oGTT

A number of studies have reported the sensitivities and specificities when comparing the WHO oGTT diagnosed diabetes with an HbA<sub>1c</sub>  $\geq 48$  mmol/mol (6.5%). Sensitivities have ranged widely from 16.7% in Austria [36] and 20.9% in Brazil [10] to 98.1% in Malaysia [37], which covers the sensitivities reported in the current study (23.8%-67.2% Table 3). Similarly, specificity of the ADA criteria versus HbA<sub>1c</sub> have varied widely from 36.7% in Malaysia [37] to 98.7% in Germany [38]. Positive predictive values have ranged from 33.3% in Poland [8] to 69% in China [39] similar to the current study (42.2%-63.6% Table 3) and negative predictive values have ranged from 74.2% in Korea [40] to 97.8% in China [41] which were lower than the current study.

A weighted kappa of 0.22 (similar to that found in Table 1 of 0.24) has been reported from Brazil [10].

### HbA<sub>1c</sub> versus ADA FPG

In the current study (Table 3), the sensitivity of HbA<sub>1c</sub> compared to the ADA FPG criteria was low overall (31.3%), but was much higher in all non-European ethnic groups (83.3% to 93.3%). These differences may reflect a faster rate of HbA<sub>1c</sub> formation in non-European populations. Previous studies have reported sensitivities of between 47% in the U.S. ARIC study [42] to 83.4% in the U.S NHANES study [43]. However, a study in Peru reported a tripling in prevalence of diabetes using the HbA<sub>1c</sub> criteria compared to the FPG criteria [44]. Specificities (96.7%-99.4% Table 3) in the current study were generally comparable to other

studies that have ranged from 89.1% in Korea [45] to 99% in Japan [46]. The positive predictive values varied widely in the current study, but the negative predictive values were generally high as has been observed previously [46, 47].

A study in Korea reported a weighted kappa of 0.60 [45], higher than 0.19 in the current study (Table 1).

### Ethnicity

Similar to the varying levels of sensitivity observed in different ethnic groups in Table 3, the NHANES survey also reported varying sensitivities by ethnicity of 58.6% in non-Hispanic whites, 75.8% in non-Hispanic blacks, 83.6% in Mexican Americans and 68.1% in others using a cut off level of HbA<sub>1c</sub>  $\geq 6.1\%$  (43 mmol/mol) [43]. A meta-analysis showed that optimal diagnostic cut points vary by age, gender and ethnicity [48].

Subtle but significant differences in the relationship between plasma glucose and HbA<sub>1c</sub> between different ethnicities have been identified in other studies, e.g. NHANES reported that non-Hispanic blacks and Mexican Americans had higher levels of HbA<sub>1c</sub> compared to non-Hispanic whites [49] and the Durable trial also reported that people of Asian, Hispanic and African descent had higher HbA<sub>1c</sub> levels compared to Caucasians [50]. These differences are similar in magnitude to those observed between the Pacific, Māori and Asians compared to Europeans in this study (Figure 2).

Individual differences in rates of HbA<sub>1c</sub> formation tend to be consistent in individuals over time [51]. The rate of formation of HbA<sub>1c</sub> can be compared with glycation of other markers such as fructosamine, which do not require entry of glucose into red cells. Patients who form HbA<sub>1c</sub> more rapidly have a so-called high glycation index with a higher mean HbA<sub>1c</sub> compared with their average ambient plasma glucose levels. Conversely those forming HbA<sub>1c</sub> less rapidly have a narrow glycation index and mounting evidence suggests that these differences may be biologically significant. Patients with more rapid formation of HbA<sub>1c</sub> are predisposed to certain complications such as nephropathy [52]. Such patients may also be predisposed to greater risk of hypoglycaemia for a given HbA<sub>1c</sub>, as suggested by a recent post-hoc analysis of subjects the ACCORD trial [53].

These differences between ethnic groups highlight the problems in using different criteria for the diagnosis of diabetes, which have been primarily based on prevalence thresholds for microvascular disease, especially retinopathy. Its value as a prognostic marker for macrovascular disease has also been shown, even after adjusting for fasting plasma glucose levels [54].

While HbA<sub>1c</sub> is effectively a 'surrogate' for average glycaemia, mounting evidence shows that it is a more reliable and useful prognostic marker for micro- and macrovascular complications than its use would be empirically justified, despite the lower sensitivity. Use of HbA<sub>1c</sub> for diagnosis would not only add convenience, but also possibly be preferable for non-Caucasian ethnic groups, who have a faster rate of HbA<sub>1c</sub> formation (wider glycation index) and therefore may be more prone to complications. Indeed, it has been argued that the diagnostic threshold for HbA<sub>1c</sub> should be lower for non-Caucasian populations such as American Blacks compared to whites [55].

## Optimal Limits

A large number of studies have calculated the optimal HbA<sub>1c</sub> cut point for the diagnosis of diabetes using the WHO oGTT and ADA criteria. Optimal cut points for HbA<sub>1c</sub> have ranged from 41 (5.9%) [8] to 50 (6.7%) [27] mmol/mol, with the majority reporting lower cut off values than the currently recommended cut off level of 48 mmol/mol (6.5%). The lower limit is similar to that found in the current study (Table 4) where we observed the highest sensitivity for HbA<sub>1c</sub> using a cut-off that maximized both sensitivity and specificity of  $\geq 40$  mmol/mol (5.8%).

## References

1. World Health Organisation (1965) Report of a WHO Expert Committee. (Tech. Rep. Ser., no. 310). WHO, Geneva.
2. World Health Organisation (1980) Expert Committee on Diabetes mellitus (Tech. Rep. Ser., no. 646). WHO, Geneva.
3. World Health Organization (1985) Diabetes Mellitus: Report of a WHO Study Group. WHO, Geneva.
4. World Health Organization (1999) Definition Diagnosis and Classification of Diabetes Mellitus and its complications. Part I: Diagnosis and Classification of Diabetes Mellitus. WHO, Geneva.
5. World Health Organization (2006) Definition and Diagnosis of Diabetes Mellitus and Intermediate hyperglycaemia. WHO, Geneva.
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20: 1183-1197.
7. The International Expert Committee (2009) International Expert Committee Report on the role of A1c assay in the diagnosis of diabetes. *Diabetes Care* 32: 1327-1334.
8. Adamska E, Waszczeniuk MG, Golonko A, Wilk J, Maliszewska K, et al. (2012) The usefulness of glycated hemoglobin A1c (HbA1c) for identifying dysglycemic states in individuals without previously diagnosed diabetes. *Adv Med Sci* 57: 296-301.
9. Bao Y, Ma Z, Li H, Zhou M, Hu C, et al. (2010) Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. *BMJ* 340: c2249.
10. Cavagnoli G, Comerlato J, Comerlato C, Renz P, Gross J, et al. (2011) HbA1c measurement for the diagnosis of diabetes: is it enough? *Diabet Med* 28: 31-15.

## Strengths and Limitations

Limitations include the fact that a single oGTT was carried out. A single FPG and 2-hr PG are not sufficient for a clinical diagnosis of dysglycaemia on an individual level, in the absence of symptoms (the full rule-set is 2 criteria, either 2 separate glucose measures or one glucose measure + symptoms), but it is adequate to demonstrate ethnic differences in HbA<sub>1c</sub> and plasma glucose. Another limitation that Asians are a mixed category of high and low risk with different metabolic profiles as Indians have central body obesity at a relatively low BMI. Our strengths include the relatively large sample size and a multiracial sample, enabling ethnic differences in HbA<sub>1c</sub> performance to be evaluated.

## Conclusion

Compared to the WHO oGTT criteria for diagnosing diabetes, FPG alone and HbA<sub>1c</sub> are significantly less sensitive, but more specific.

**Acknowledgments:** This survey was funded by the Health Research Council of New Zealand. We thank the technical and clerical staff who conducted the study so capably and efficiently.

11. Kramer C, Araneta M, Barrett-Connor E (2010) A1c and diabetes diagnosis: The Rancho Bernardo Study. *Diabetes Care* 33: 101–103.
12. Selvin E, Steffes M, Ballantyne C, Hoogeveen R, Coresh J, et al. (2011) Racial difference in glyceic markers: a cross-sectional analysis of community-based data. *Ann Intern Med* 154: 303-309.
13. Herman W, Dungan K, Wolffenbuttel B, Buse J, Fahrback J, et al. (2009) Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-Anhydroglucitol in over 2000 patients with type 2 diabetes. *J Clin Endocrinol Metab* 94: 1689-1694.
14. Jorgensen M, Bjerregaard P, Borch-Johnsen K, Witte D (2010) New diagnostic criteria for diabetes: Is the change from glucose to HbA1c possible in all populations? *J Clin Endocrinol Metab* 95: E333-E336.
15. American Diabetes Association (2015) Diagnosis and classification of diabetes mellitus. *Diabetes Care* 38 (suppl 1): S8-S16.
16. Statistics New Zealand (2006) 2006 Census [Online]. [cited 2014 Oct 20].
17. Alberti K, Zimmet P (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabetic Medicine* 15: 539-553.
18. Dunn G (1992) Design and analysis of reliability studies. New York: John Wiley & Sons. pp 30-38.
19. Altman D, Gardiner M (2000) Statistics with confidence. 2nd ed London: BMJ Books.
20. Greenhouse S, Mantel N (1950) The evaluation of diagnostic tests. *Biometrics* 6: 399-412.
21. Alqahtani N, Khan W, Alhumaidi M, Ahmed Y (2013) Use of glycated hemoglobin in the diagnosis of diabetes mellitus and pre-diabetes and role of fasting plasma glucose, oral glucose tolerance test. *Int J Prev Med* 4: 1025-1029.
22. Zhang Y, Ma W, Thomas G, Xu Y, Lao X, et al. (2012) Diabetes and pre-diabetes as determined by glycated A1c and glucose levels in a developing southern Chinese population. *PloS One* 7: e37269
23. Costa B, Barrio F, Cabre J-J, Pinol J-L, Cos F-X, et al. (2011) Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population. *Diabet Med* 28: 1234-1237.
24. Janghorbani M, Amini M (2012) Incidence of type 2 diabetes by HbA1c and OGTT: the Isfahan Diabetes Prevention Study. *Acta Diabetol* 49 (Suppl 1): S73-S79.
25. Tankova T, Chakarova N, L D, Atanassova I (2012) Assessment of HbA1c as a diagnostic tool in diabetes and prediabetes. *Acta Diabetol* 49: 371-378.
26. Costa B, Barrio F, Pinol J, Cabre J, Munder A, et al. (2013) Shifting the glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Risk Diabetes Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventative-strategy. *BMC Medicine* 11: <http://www.biomedcentral.com/1741-7015/1711/1745>.
27. Engelgau M, Thompson T, Herman W, Boyle J, Aubert R, et al. (1997) Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. *Diabetes Care* 20: 785-791.
28. Valdes S, Botas P, Delgado E, Alvarez F, Diaz-Cadorniga F (2011) HbA1c in the prediction of type 2 diabetes compared with fasting and 2-h post-challenge plasma glucose; The Asturias study (1998-2005). *Diabetes & Metabolism* 37: 27-32.
29. Khera P, Joiner C, Carruthers A, Lindsell C, Smith E, et al. (2008) Evidence for interindividual heterogeneity in the glucose gradient across the human red blood membrane and its relationship to hemoglobin glycation. *Diabetes* 57: 2445-2452.
30. Cohen R, Franco R, Khera P, Smith E, Lindsell C, et al. (2008) Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. *Blood Press* 112: 4284-4291.
31. Kim C, Bullard KM, Herman WH, Beckles GL (2010) Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999–2006. *Diabetes Care* 33: 780-785.

32. Selvaraj N, Bobby Z, Sathiyapriya V (2006) Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. *Clinica Chimica Acta* 366: 190-195.
33. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, et al. (2010) Common variants at 10 genomic loci influence hemoglobin A1c levels via glyceemic and nonglyceemic pathways. *Diabetes* 59: 3229-3239.
34. De Vegt F, Dekker JM, Stehouwer CDA, Nijpels G, Bouter LM, et al. (1998) The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance. Poor agreement in the Hoorn Study. *Diabetes Care* 21: 1686-1690.
35. Ko G, Woo J, Chan J, Cockram C (1998) Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. *Diabetes Care* 21: 2094-2097.
36. Farhan S, Jarai R, Tentzeris I, Willer A, Samaha E, et al. (2012) Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease. *Clin Res Cardiol* 101: 625-630.
37. Wan Nazaimoon W, Md Isa A, Wan Mohamad W, Khir A, Kamaruddin N, et al. (2013) Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. *Diabet Med* 30: 825-828.
38. Peter A, Fritsche N, Heni M, Schleicher E (2011) Diagnostic value of HbA1c for type 2 diabetes mellitus in a population at risk. *Exp Clin Endocrinol Diabetes* 119: 234-237.
39. Dong X, Liu Y, Sun Y, Fu F, Wang S, et al. (2011) Comparison of HbA1c and OGTT criteria to diagnoses diabetes among Chinese. *Exp Clin Endocrinol Diabetes* 119: 366-369.
40. Lee H, Oh J-Y, Sung Y-A, Kim D-J, Kim S-H, et al. (2012) Optimal hemoglobin A1c cutoff value for diagnosing type 2 diabetes mellitus in Korean Adults. *Diab Res Clin Prac* 99: 231-236.
41. Huang H, Peng G, Lin M, Zhang K, Wang Y, et al. (2013) The diagnostic threshold of HbA1c and impact of its use on diabetes prevalence - A population-based survey of 6898 Han participants from southern China. *Prev Med* 57: 345-350.
42. Selvin E, Brancati F, Steffes M, Coresh J, Gregg E (2011) Performance of A1c for the classification and prediction of diabetes. *Diabetes Care* 34: 84-89.
43. Rohlfing C, Little RW, H-M, England J, Madsen R, Harris M, et al. (2000) Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. *Diabetes Care* 23: 187-191.
44. Miranda J, Bernabe-Ortiz A, Stanojevic S, Malaga G, Gilman R, et al. (2011) A1c as a diagnostic criteria for diabetes in low- and middle-income settings: evidence from Peru. *PloS One* 6: e18069.
45. Kim H-J, Choi E, Park E, Cheong Y, Lee H-Y, et al. (2011) The utility of HbA1c as a diagnostic criterion for diabetes. *Korean J Fam Med* 32: 383-389.
46. Heianza Y, Hara S, Arase Y, Saito K, Tsuji H, et al. (2012) Impact of introducing HbA1c into the diagnostic criteria on prevalence and cardiovascular risk profiles of individuals with newly diagnosed diabetes in Japan: The Toranomon Hospital Health Management Study 2 (TOPICS 2). *Diab Res Clin Prac* 95: 283-290.
47. Lipska K, De Rekeneire N, Van Ness P, Johnson K, Kanaya A, et al. (2010) Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. *J Clin Endocrinol Metab* 95: 5289-5295.
48. Bennett C, Guo M, Dharmage S (2007) HbA1c as a screening test for detection of type 2 diabetes: a systematic review. *Diabet Med* 24: 333-343.
49. Herman W, Cohen R (2012) Racial and Ethnic Differences in the Relationship between HbA1c and Blood Glucose: Implications for the Diagnosis of Diabetes. *J Clin Endocrinol Metab* 97: 1067-1072.
50. Wolffenbuttel B, Herman W, Gross J, Dharmalingham M, Jiang H, et al. (2013) Ethnic differences in glyceemic markers in patients with type 2 diabetes. *Diabetes Care* 36: 2931-2936.
51. Wilson D, Xing D, Cheng J, Beck R, Hirsch I, et al. (2011) Persistence of individual variations in glycated hemoglobin Analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. *Diabetes Care* 34: 1315-1317.

52. Cosson E, Banu I, Cussac-Pillegand C, Chen Q, Chiheb S, et al. (2013) Glycation gap is associated with macroproteinuria but not with other complications in patients with type 2 diabetes. *Diabetes Care* 36: 2070-2076.
53. Hempe J, Liu S, Myers L, McCarter R, Buse J, et al. (2015) The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. *Diabetes Care*: DOI: 10.2337/dc2314-1844.
54. Selvin E, Steffes M, Zhu H, Matsushita K, Wagenknecht L, et al. (2010) Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. *N Engl J Med* 362: 800-811.
55. Tsugawa Y, Mukamal K, Davis R, Taylor W, Wee C (2012) Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? *Ann Int Med* 157: 153-159.
56. Mannucci E, Ognibene A, Sposato I, Brogi M, Gallori G, et al. (2003) Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. *Acta Diabetol* 40: 181-186.
57. Ko T, Chan J, Yeung V, Chow C-C, Tsang L, et al. (1998) Combined use of a fasting glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high risk subjects. *Diabetes Care* 21: 1221-1225.
58. Metcalf PA, Scragg RKR (2000) Comparison of the WHO and ADA criteria for diagnosis of glucose status in a middle-aged New Zealand population. *Diabetic Med* 49: 169-180.

**Appendix 1:** Comparison of diagnostic criteria for glucose intolerance by the 1997 ADA and 1998 WHO criteria by ethnicity. Values are number (row %).

	ADA fasting criteria				HbA <sub>1c</sub> (mmol/mol)		
	Normal	IFG	Diabetes	Total	<39	39-<48	≥ 48
<b>WHO criteria</b>							
<b>European</b>	Weighted kappa 0.37 (0.30-0.45)				Weighted kappa 0.27 (0.22-0.33)		
Normal	1,384 (85.3)	45 (2.8)	0	1,429 (88.1)	1,126 (69.4)	300 (18.5)	3 (0.2)
IGT	127 (7.8)	24 (1.5)	0	151 (9.3)	65 (4.0)	81 (5.0)	5 (0.3)
Diabetes	9 (0.6)	15 (0.9)	18 (1.1)	42 (2.6)	10 (0.6)	22 (1.4)	10 (0.6)
Total	1,520 (93.7)	84 (5.2)	18 (1.1)	1,622 (100.0)	1,201 (74.0)	403 (24.9)	18 (1.1)
<b>HbA<sub>1c</sub> (mmol/mol)</b> Weighted kappa 0.21 (0.16-0.26)							
< 39	1,172 (72.3)	344 (21.2)	4 (0.2)	1,520 (93.7)			
39-<48	27 (1.7)	50 (3.1)	7 (0.4)	84 (5.2)			
≥ 48	2 (0.1)	9 (0.4)	7 (0.4)	18 (1.1)			
Total	1,201 (74.0)	403 (24.9)	18 (1.1)	1,622 (100.0)			

**WHO criteria**

Māori	Weighted kappa 0.44 (0.35-0.53)				Weighted kappa 0.25 (0.19-0.31)			
Normal	694 (81.0)	31 (3.6)	0	725 (84.6)	448 (52.3)	272 (31.7)	5 (0.6)	
IGT	76 (8.9)	23 (2.7)	0	99 (11.6)	28 (3.3)	59 (6.9)	12 (1.4)	
Diabetes	7 (0.8)	11 (1.3)	15 (1.8)	33 (3.9)	5 (15.2)	11 (3.2)	17 (50.0)	
Total	777 (90.7)	65 (7.6)	15 (1.8)	857 (100.0)	481 (56.1)	342 (39.9)	34 (4.0)	

**HbA<sub>1c</sub> (mmol/mol)** Weighted kappa 0.19 (0.14-0.25)

< 39	464 (59.7)	302 (38.9)	11 (1.4)	1,520 (93.7)
39-<48	17 (26.2)	39 (60.0)	9 (13.9)	84 (5.2)
≥ 48	0 (0.0)	1 (6.7)	14 (93.3)	18 (1.1)
Total	481 (56.1)	342 (39.9)	34 (4.0)	857 (100.0)

**WHO criteria**

Pacific	Weighted kappa 0.60 (0.52-0.67)				Weighted kappa 0.27 (0.22-0.32)			
Normal	569 (76.3)	37 (5.0)	0	606 (81.2)	285 (38.2)	301 (40.3)	20 (2.7)	
IGT	60 (8.0)	22 (3.0)	0	82 (11.0)	13 (1.8)	47 (6.3)	22 (2.9)	
Diabetes	5 (0.7)	14 (1.9)	39 (5.2)	58 (7.8)	2 (3.5)	17 (29.3)	39 (67.2)	
Total	634 (85.0)	73 (9.8)	39 (5.2)	746 (100.0)	300 (40.2)	365 (48.9)	81 (10.9)	

**HbA<sub>1c</sub> (mmol/mol)** Weighted kappa 0.25 (0.20-0.30)

< 39	294 (39.4)	318 (42.6)	22 (3.0)	634 (85.0)
39-<48	6 (0.8)	40 (5.4)	27 (3.6)	73 (9.8)
≥ 48	0 (0.0)	7 (0.9)	32 (4.3)	39 (5.2)
Total	300 (40.2)	365 (48.9)	81 (10.9)	746 (100.0)

**WHO criteria**

Asian	Weighted kappa 0.50 (0.34-0.66)				Weighted kappa 0.37 (0.25-0.49)			
Normal	196 (81.7)	8 (3.3)	0	204 (85.0)	152 (63.3)	51 (21.3)	1 (0.4)	
IGT	15 (6.3)	7 (2.9)	0	22 (9.2)	8 (3.3)	11 (4.6)	3 (1.3)	
Diabetes	5 (2.1)	3 (1.3)	6 (2.5)	14 (5.8)	1 (0.4)	6 (2.5)	7 (2.9)	
Total	216 (90.0)	18 (7.5)	6 (2.5)	240 (100.0)	161 (67.1)	68 (28.3)	11 (4.6)	

**HbA<sub>1c</sub> (mmol/mol)** Weighted kappa 0.31 (0.18-0.43)

< 39	156 (65.0)	58 (24.2)	2 (0.8)	216 (90.0)
39-<48	5 (2.1)	9 (3.7)	4 (1.7)	18 (7.5)
≥ 48	0 (0.0)	1 (0.4)	5 (2.1)	6 (2.5)
Total	161 (67.1)	68 (28.3)	11 (4.6)	240 (100.0)

IGT = impaired glucose tolerance; IFG = impaired fasting glucose.

Only 35.7% of European, 33.3% of Māori, 24.1% of Pacific, and 21.4% of Asian participants with diabetes by WHO criteria would have been classified as IFG by ADA criteria.

Diagnostic rates of diabetes were lower using the ADA FPG criteria compared to WHO oGTT criteria in all ethnic groups (Appendix 1). Using a FPG cut-off of 7.0 mmol/L (126 mg/dL) only would miss 46.9% of participants with WHO diagnosed diabetes, comprising 57.1% of Europeans, 54.5% of Māori, 32.8% of Pacific and 57.1% of Asian people. This indicates that using a FPG (ADA) criterion alone is relatively more sensitive for Pacific people, compared with those of other ethnicities.

Using an HbA<sub>1c</sub> cutoff of  $\geq 48$  mmol/mol as the sole criterion would miss 59.2% of participants with WHO diagnosed diabetes, comprising 76.2% Europeans, 88.4% Māori, 50.0% Pacific, and 88.4% of Asian people. This indicates that the HbA<sub>1c</sub> cutoff is particularly insensitive in Māori and Asian people, but relatively more sensitive for Pacific people.

The percentage agreements between the two diagnostic criteria were similar between ethnic groups, being 87.9% in European, 85.4% in Māori, 84.5% in Pacific, and 87.1% in Asian people. Prevalence rates of IGT compared with IFG were slightly higher in all ethnic groups.

The weighted  $\kappa$ 's were 0.44 (0.35-0.53) for Māori, 0.60 (0.52-0.67) for Pacific, and 0.50 (0.34-0.66) for Asian participants, indicating moderate agreement, and 0.37 (95% CI 0.30-0.45) for Europeans, indicating fair agreement.

**Appendix 2:** AUC's (95% CI) from receiver operator curves for impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG).

	AUC (95% CI)
<b>IGT</b>	
HbA <sub>1c</sub>	0.76 (0.73, 0.78)
FPG	0.76 (0.73, 0.79)
<b>IFG</b>	
HbA <sub>1c</sub>	0.76 (0.72, 0.81)
2-hr PG	0.67 (0.61, 0.72)

The areas under the curves predicting IGT for HbA<sub>1c</sub> and FPG were moderately predictive (Appendix 2). FPG and HbA<sub>1c</sub> were not significantly different ( $P = 0.7420$ ). The AUC's predicting IFG for HbA<sub>1c</sub> was moderately predictive, whereas the AUC's for 2-hr PG was less predictive. All tests were significantly different from each other (all  $P < 0.0001$ ).

Please Submit your Manuscript to Cresco Online Publishing  
<http://crescopublications.org/submitmanuscript.php>